The BioMensio biosensors allow cost efficient application development for businesses and governmental organizations in food and beverage, healthcare, security and defense segments as well as environmental monitoring area", comments Ilari Antila, CEO.
Tampere, Finland (PRWEB UK) 29 November 2016
BioMensio Ltd, announces today a €2.5 million funding round from private investors, VTT Ventures, Siemens Technology Accelerator and Tekes, the Finnish Funding Agency for Innovation. In addition to the capital injection, the investor consortium provides BioMensio with access to extensive knowledge and an industry network.
"BioMensio is now set to develop a smart handheld bio-screening sensor and associated cloud services to determine the presence of specific biomolecules. Rapid and accurate on-site testing enables fast and targeted action in the presence of multiple unwanted substances from a biological liquid based sample. The BioMensio biosensors allow cost efficient application development for businesses and governmental organizations in food and beverage, healthcare, security and defense segments as well as environmental monitoring area", comments Ilari Antila, CEO.
Universality and simplicity are the main advantages of BioMensio label-free technologies. No labelling or analyte modifications are necessary unlike with traditional techniques. This makes the BioMensio sensor inherently universal and applicable to any analyte, or even DNA, on the lab-on-a-chip platform.
Joni Leinvuo, CTO BioMensio: "BioMensio devices will be powered by cost effective, well-scaling Mass-Sensitive Micro-Array (MSMA) technology. The sensing platform consists of microfluidics and an array of microscopic weighing scale pixels. Mass sensitive transducer chips are based on patented BioMensio Film-Bulk Acoustic Resonance (FBAR) technology combined with Application Specific Integrated Circuits (ASIC) - two technologies largely applied in high volume mobile device industries."
About BioMensio Ltd
BioMensio Ltd (http://www.biomensio.com) was established to build on international research programs and intellectual property of more than 15 patent families. BioMensio technologies result from ten years of science and combines research at VTT Technical Research Centre of Finland with know-how of Siemens’ Research Labs.
About VTT Technical Research Centre of Finland and VTT Ventures
VTT Technical Research Centre of Finland is the leading research and technology company in the Nordic countries, and has a national science and research mandate in Finland. It has over 70 years of experience supporting clients’ growth with top-level research and science-based results. VTT uses 4,000,000 hours of brainpower to develop new technologies every year. More information: http://www.vttresearch.com
VTT Ventures is the venture arm of VTT with 20 companies in its portfolio. It spins out and invests in the most promising VTT technologies with strong founders. More information: http://www.vttventures.fi
About Siemens Technology Accelerator GmbH
The Siemens Technology Accelerator GmbH (STA) has been established in 2001 as a fully owned subsidiary of Siemens AG. STA’s mission is to identify and implement the best possible strategy for the external commercialization of innovative Siemens technologies that fall outside of Siemens core business.
The STA team has extensive expertise in setting-up technology start-ups and in the sale and licensing of technologies. STA employs a proven three-stage approach for external commercialization, beginning with evaluation, through deal transaction, and on to portfolio management.
More information: http://www.siemens.com/sta